Regeneron and Intellia expand collaboration on gene editing therapies
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) have expanded their research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.